AC Immune’s PET Tracer Shows First In Vivo Brain Images of TDP-43 Pathology
Event summary
- AC Immune presented first in vivo images of brain TDP-43 pathology using PET tracer ACI-19626 at AD/PD™ 2026.
- Phase 1 trial data showed significantly higher tracer uptake in patients with genetically defined frontotemporal dementia (FTD).
- ACI-19626 demonstrated good safety, tolerability, and a suitable pharmacokinetic profile for human brain imaging.
- Part 1 of the trial is expected to complete in H1 2026, with Part 2 expanding to include up to 30 patients with FTD, ALS, or LATE.
The big picture
AC Immune’s success with ACI-19626 could revolutionize the diagnosis of neurodegenerative diseases like FTD, ALS, and LATE, where TDP-43 pathology is a key marker. The ability to detect this pathology in vivo could enable earlier intervention and more targeted treatments, addressing a significant unmet need in the field. The company’s proprietary technology platforms, SupraAntigen® and Morphomer®, position it as a leader in precision prevention for neurodegenerative conditions.
What we're watching
- Diagnostic Potential
- How ACI-19626 will affect early diagnosis and precision medicine across neurodegenerative diseases.
- Clinical Validation
- Whether the final Part 1 data and Part 2 expansion will confirm ACI-19626’s role in differential diagnosis.
- Market Adoption
- The pace at which AC Immune can secure partnerships or regulatory approvals for broader clinical use.
Related topics